在線客服

咨詢熱線

磷酸西格列汀治療老年2型糖尿病的臨床效果及安全性觀察

作者:未知

  [摘要] 目的 探討磷酸西格列汀治療老年2型糖尿病的臨床效果及安全性。 方法 收集我院于2016年3月~2019年3月期間收治的老年2型糖尿病患者共105例,按照隨機數字表法分成兩組,對照組52例,研究組53例,兩組患者均給予常規治療及運動生活指導,在此基礎上,對照組用二甲雙胍治療,研究組用磷酸西格列汀治療,兩組均治療3個月。比較兩組空腹血糖(FBG),餐后2 h血糖(2 hPG)、糖化血紅蛋白(HbA1c)、體質量指數(BMI)、胰島素抵抗指數(HOMA-IR)、空腹胰島素(FINs)水平。 結果 (1)治療后兩組FBG、2 hPG、HbA1c較治療前明顯下降,差異有統計學意義(P<0.05);研究組FBG、2 hPG、HbA1c低于對照組,差異有統計學意義(P<0.05)。(2)治療后兩組BMI、HOMA-IR較治療前明顯下降,FINs較治療前明顯升高,差異有統計學意義(P<0.05);研究組BMI、HOMA-IR低于對照組,FINs高于對照組,差異有統計學意義(P<0.05)。(3)研究組低血糖發生率低于對照組,兩組差異有統計學意義(P<0.05)。 結論 磷酸西格列汀治療老年2型糖尿病能有效控制血糖和血紅蛋白水平,改善患者的胰島素指標,且有較高的安全性。
  [關鍵詞] 2型糖尿病;磷酸西格列汀;空腹血糖;糖化血紅蛋白;胰島素指數;低血糖
  [中圖分類號] R587.1          [文獻標識碼] B          [文章編號] 1673-9701(2019)27-0108-04
  [Abstract] Objective To investigate the clinical efficacy and safety of sitagliptin phosphate in the treatment of type 2 diabetes mellitus in the elderly. Methods A total of 105 elderly patients with type 2 diabetes mellitus admitted to our hospital from March 2016 to March 2019 were enrolled. The patients were divided into two groups according to the random number table method, with 52 patients in the control group and 53 patients in the study group. Both groups of patients were given routine treatment and sports life guidance. On the above basis, the control group was treated with metformin, and the study group was treated with sitagliptin phosphate. Both groups were treated for 3 months. Fasting blood glucose(FBG), postprandial 2 hPG, glycosylated hemoglobin(HbA1c), body mass index(BMI), insulin resistance index(HOMA-IR), and fasting insulin(FINs) levels were compared between the two groups. Results (1)FBG, 2 hPG and HbA1c after treatment were significantly decreased compared with those before treatment, and the difference was significant(P<0.05). The FBG, 2 hPG and HbA1c in the study group were lower than those in the control group, and the difference was statistically significant(P<0.05). (2) The BMI and HOMA-IR of the two groups after treatment were significantly lower than those before treatment, and the FINs after treatment were significantly higher than before treatment(P<0.05). The BMI and HOMA-IR of the study group were lower than those of the control group, and FINs in the study group were significantly higher than those of the control group, and the difference was statistically significant(P<0.05). (3)The incidence of hypoglycemia in the study group was lower than that in the control group, and the difference between the two groups was statistically significant(P<0.05). Conclusion Sitagliptin phosphate is effective in controlling blood glucose and hemoglobin levels in elderly patients with type 2 diabetes, improving insulin levels in patients and has higher safety.   綜上所述,磷酸西格列汀治療老年2型糖尿病能有效控制血糖和血紅蛋白水平,改善患者的胰島素指標,且有較高的安全性,效果明顯優于二甲雙胍,臨床價值較高,建議臨床推廣應用。
  [參考文獻]
  [1] 李芳.利格列汀對老年2型糖尿病患者的有效性及安全性分析[J].中國現代藥物應用,2019,13(7):88-89.
  [2] 孫勝奎.西格列汀聯合大劑量胰島素治療老年2型糖尿病的臨床效果及安全性評價[J].臨床合理用藥雜志,2019,12(5):81-82.
  [3] 王琪,李楠,劉敏燕,等.磷酸西格列汀治療老年2型糖尿病的有效性及安全性觀察[J].中國醫藥,2015,10(6):831-833.
  [4] 陳麗.磷酸西格列汀聯合二甲雙胍治療初發2型糖尿病的臨床效果[J].中國實用醫刊,2018,45(19):121-123.
  [5] 謝嵐,毛欣.西格列汀聯合甘精胰島素治療2型糖尿病的有效性和安全性觀察[J].四川醫學,2013,34(6):824-826.
  [6] 陳紅霞,史婷婷,袁群,等.西格列汀與二甲雙胍聯用治療老年2型糖尿病的療治效觀察[J].微循環學雜志,2019, 29(1):18-22.
  [7] 高婷婷.西格列汀聯合甘精胰島素治療老年2型糖尿病的療效及對炎性因子的影響[J].中國藥物與臨床,2019,19(6):969-971.
  [8] 趙國棟,龐俊玲.沙格列汀聯合阿卡波糖治療老年2型糖尿病初診患者的臨床效果[J].中國實用醫刊,2019, 46(1):108-110.
  [9] 劉娜.磷酸西格列汀聯合甘精胰島素對老年2型糖尿病患者的影響[J].社區醫學雜志,2017,15(8):68-69.
  [10] 李光偉.關注血糖達標與低血糖風險之間的平衡[J].中華內分泌代謝雜志,2012,28(1):1-3.
  [11] 中華醫學會糖尿病學分會.中國2型糖尿病防治指南(2010年版)[M].北京:北京大學醫學出版社,2011:16-17.
  [12] 楊秋偉,張利川,馬玲玲.胰島素控制不佳的2型糖尿病并冠心病患者加用磷酸西格列汀臨床觀察[J].中國實用醫刊,2014,41(22):26-28.
  [13] 劉東海.磷酸西格列汀片與二甲雙胍治療初發性2型糖尿病的臨床療效觀察[J].中國實用醫藥,2018,13(29):137-138.
  [14] 周焰,韓亮.磷酸西格列汀聯合二甲雙胍治療初發型2型糖尿病患者的療效[J].安徽醫學,2017,38(4):476-478.
  [15] 楊娜,魏青梅,王霞.磷酸西格列汀聯合二甲雙胍治療老年2型糖尿病療效及對患者血糖、胰島素及脂代謝的影響[J].中國實用醫刊,2017,44(15):63-66.
  (收稿日期:2019-07-02)
轉載注明來源:http://www.361tx.com/6/view-15066966.htm

?
天天啪啪,天天啪一啪,天天啪影院,啪啪在线影院免费